Sanofi India has entered into a marketing and distribution agreement with Emcure Pharmaceuticals for its oncology portfolio in India.
Healthcare firm Sanofi India gained nearly 2 percent on Wednesday after it has entered into a marketing and distribution agreement with Emcure Pharmaceuticals for its oncology portfolio in India. As per the agreement, while Sanofi will continue to own its oncology range (comprising four brands namely Taxotere, Jevtana, Fludara and Fasturtec), Emcure will market and distribute these brands through its specialty unit.
"Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies," said Shailesh Ayyangar, vice president - South Asia and Managing Director - Sanofi India Limited and Sanofi – Synthelabo (India). Sanofi will continue to provide strong scientific and medical support to Emcure’s already well-established and fast growing Oncology business, he added.
Healthcare firm Sanofi India gained nearly 2 percent on Wednesday after it has entered into a marketing and distribution agreement with Emcure Pharmaceuticals for its oncology portfolio in India. As per the agreement, while Sanofi will continue to own its oncology range (comprising four brands namely Taxotere, Jevtana, Fludara and Fasturtec), Emcure will market and distribute these brands through its specialty unit.
"Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies," said Shailesh Ayyangar, vice president - South Asia and Managing Director - Sanofi India Limited and Sanofi – Synthelabo (India). Sanofi will continue to provide strong scientific and medical support to Emcure’s already well-established and fast growing Oncology business, he added.
No comments:
Post a Comment